Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Core Insights - Corbus Pharmaceuticals Holdings Inc. announced the release of an abstract for its Phase 1/2 clinical study at the ESMO Congress 2025, focusing on safety data from 70 participants and updated efficacy data from 167 enrolled participants [2][4] - The ongoing clinical trial evaluates the safety, pharmacokinetics, and efficacy of CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4, primarily in patients with advanced solid tumors such as head and neck squamous cell carcinoma (HNSCC) and cervical tumors [5][6] Clinical Study Details - The clinical study includes 167 enrolled participants, with 122 evaluable for efficacy across various tumor types: HNSCC (n=41), cervical (n=37), metastatic urothelial tumors (n=23), and others (n=21) [2][5] - The poster presentation titled "Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours" will take place on October 19, 2025 [3] Event Information - Corbus will host an in-person and virtual KOL event to discuss the data, featuring insights from leading experts in HNSCC, scheduled for October 19, 2025, at the Berlin Germany Marriott [4][9] Product Information - CRB-701 (SYS6002) is designed to target Nectin-4, utilizing a site-specific, cleavable linker and a homogeneous drug-antibody ratio of 2, with monomethyl auristatin E (MMAE) as the cytotoxic payload [6] - The FDA has granted two Fast Track designations to CRB-701 for HNSCC and cervical cancer [6][7] Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, with a pipeline that includes CRB-701, CRB-601 (an anti-integrin monoclonal antibody), and CRB-913 (a CB1 receptor inverse agonist for obesity treatment) [7]